Table 4.
Median levels of immune biomarkers and the association with term and preterm preeclampsia (normotensive women are the reference).
| Preterm Preeclampsia | Term Preeclampsia | |||
|---|---|---|---|---|
| Biomarker | Median pg/ml (range) | * Effect estimate (p-value) | Median pg/ml (range) | ** Effect estimate (p-value) |
| RANTES | 37.3(7.2–161.0) | −0.13(0.3323) | 35.7(2.3–161.0) | −0.14(0.3323) |
| IL4r | 353.0(4.0–4000.0) | −0.01(0.6410) | 384.0(4.0–4000.0) | −0.01(0.0733) |
| IL6ra | 113.0(20.1–280.2) | −0.01(0.7276) | 111.8(29.4–400.00) | −0.05(0.7774) |
| MIF | 63.1(0.58–101.0) | −0.20(0.0530) | 78.3(0.1–101.0) | −0.02(0.8157) |
| MIP | 599.6(10.0–1422.0) | −0.07(0.1403) | 681.0(10.0–10000.0) | 0.03(0.4135) |
| TNFR1 | 5.3(0.08–15.2) | −0.006(0.9206) | 5.6(0.1–31.33) | 0.1(0.1934) |
| TNFα | 4.0(4.0–1770.0) | *** | 4.0(4.0–1550.0) | *** |
| IL6 | 4.0(4.0–392.0) | −0.04(0.4585) | 4.0(4.0–4000.0) | 0.04(0.2267) |
| IL4 | 4.0(4.0–297.0) | −0.1(0.0578) | 23.0(4.0–950.0) | 0.01(0.8914) |
| IL5 | 25.0(4.0–213.0) | −0.05(0.5563) | 26.0(4.0–802.9) | −0.007(0.9067) |
| IL12 | 4.0(4.0–932.0) | −0.01(0.3925) | 6.0(4.0–2764.0) | 0.01(0.7615) |
| IL1α | 4.0(4.0–262.0) | *** | 4.0(4.0–627.4) | *** |
| IL1β | 199.0(4.0–985.0) | −0.17(0.0065) | 229.0(4.0–4000.0) | −0.10(0.0230) |
| IL8 | 4.0(4.0–1160.0) | −0.1(0.2595) | 4.0(4.0–4000.0) | 0.02(0.4043) |
| IL10 | 230.0(4.0–989.0) | −0.04(0.4072) | 225.0(4.0–4000.0) | −0.01(0.6078) |
| IFNγ | 123.0(4.0–1455.0) | 0.03(0.4557) | 106.0(4.0–3726.0) | 0.0(0.4390) |
| IL18 | 3.0(0.2–11.0) | −0.01(0.9633) | 2.9(0.1–11.0) | 0.13(0.0581) |
| TGFβ | 740.0(39.0–5457.0) | −0.02(0.6847) | 1061.0(39.0–10256.0) | 0.06(0.0661) |
| TNFβ | 370.0(10.0–2156.0) | −0.01(0.7571) | 555.0(10.0–4398.0) | 0.1(0.0496) |
*
Indicates that biomarker had upper limit of detection (LOD )
**
Immune markers were transformed to log (base 2) and adjusted for body mass index and smoking using logistic regression. Normotensive women were the reference group.
***
Model 2 was not utilized as 75% of subjects measured beyond the LOD.